Comparative Analysis of Somatic Variants in Paired Pre- and Post-Neoadjuvant Chemotherapy Samples of Locally Advanced Hormone Receptor-Positive Breast Cancer
This study identifies the PIK3CA p.H1047R mutation as a potential predictive biomarker for resistance to neoadjuvant chemotherapy in hormone receptor-positive locally advanced breast cancer, while noting the absence of ESR1 mutations in this setting compared to metastatic cases.